Sarah Helen Wigfield, PHARMD | |
9200 W Wisconsin Ave, Milwaukee, WI 53226-3522 | |
(414) 805-5115 | |
Not Available |
Full Name | Sarah Helen Wigfield |
---|---|
Gender | Female |
Speciality | Pharmacist |
Location | 9200 W Wisconsin Ave, Milwaukee, Wisconsin |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1083286314 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
183500000X | Pharmacist | 20917-40 (Wisconsin) | Primary |
Mailing Address | Practice Location Address |
---|---|
Sarah Helen Wigfield, PHARMD 9200 W Wisconsin Ave, Milwaukee, WI 53226-3522 Ph: () - | Sarah Helen Wigfield, PHARMD 9200 W Wisconsin Ave, Milwaukee, WI 53226-3522 Ph: (414) 805-5115 |
News Archive
When the end draws near, Dr. Roger Kligler, a retired physician with incurable, metastatic prostate cancer, wants the option to use a lethal prescription to die peacefully in his sleep.
Patients hospitalized with advanced cirrhosis, a chronic and degenerative disease of the liver, are at increased risk of death. The tools currently used to assess that risk are limited in predicting which patients will need a liver transplant and which will be healthy enough to survive transplantation.
The Pulmonary Fibrosis Foundation today announced that, in partnership with the American Thoracic Society (ATS) and Coalition for Pulmonary Fibrosis (CPF), $400,000 in new pulmonary fibrosis research grants as part of the 2010 ATS Partner Award Program for Pulmonary Fibrosis Research.
Medical research advocates warn Congress about the dire impact that automatic spending cuts scheduled to take effect in January would have on efforts to control disease and develop life-saving treatments. Also in the news, how the concept of "fast-track" Food and Drug Administration approvals is playing on Capitol Hill.
Bristol-Myers Squibb Company and Pfizer announced today that the U.S. Food and Drug Administration (FDA) has extended the action date by three months for the New Drug Application (NDA) for Eliquis (apixaban) for the prevention of stroke and systemic embolism in patients with atrial fibrillation.
› Verified 1 days ago
Robin L Berk, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1134 W North Ave, Third Floor, Milwaukee, WI 53205 Phone: 414-727-3005 | |
Kevin Bozymski, PHARMD, BCPS Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1155 N Mayfair Rd, Milwaukee, WI 53226 Phone: 414-955-8950 | |
Hanna Dehnert, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 3003 W Good Hope Rd, Milwaukee, WI 53209 Phone: 414-540-9236 | |
Belaynesh Dejene Feleke, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 5929 W Lisbon Ave, Milwaukee, WI 53210 Phone: 414-442-9233 | |
Ting Chen, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 3030 W Villard Ave, Milwaukee, WI 53209 Phone: 414-536-3378 | |
Matthew Olson, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2920 W Dakota St, Milwaukee, WI 53215 Phone: 262-957-8239 | |
Michael Sean Stiewe, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 3237 S 16th St, Milwaukee, WI 53215 Phone: 414-647-5043 |